S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to ‘BBB’ on continued good business momentum; outlook stable
London, 8 May 2025 – S&P has today announced that it has raised its long-term issuer credit rating on Hikma Pharmaceuticals PLC (Hikma, Company) and its $500 million notes outstanding due July 9, 2025, issued out of Hikma Finance USA LLC, to ‘BBB’ from ‘BBB-‘ with a stable outlook. S&P said its rating action reflects Hikma’s good business momentum and ability to maintain healthy growth prospects and stable credit metrics.
Khalid Nabilsi, CFO of Hikma said: “I am pleased that S&P have upgraded Hikma today, strengthening our investment grade rating and confirming our solid market position as well as our track record of profitability and cash generation.”